Hypothalamic obesity in children: Pathophysiology to clinical management

Journal of Pediatric Endocrinology and Metabolism

Volumn 28, Issue 5-6, 2015, Pages 503-513

  Haliloglu, Belma ^a   Bereket, Abdullah ^b  

^a Diyarbakir Children Hospital   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

children; craniopharygioma; hypothalamus; obesity

Indexed keywords

CAFFEINE; DEXAMPHETAMINE; DIAZOXIDE; EPHEDRINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; MELATONIN; METFORMIN; OCTREOTIDE; PIROMELATINE; PSYCHOTROPIC AGENT; SIBUTRAMINE;

BARDET BIEDL SYNDROME; BARIATRIC SURGERY; BASAL METABOLIC RATE; BILIOPANCREATIC BYPASS; BRAIN TUMOR; CALORIC INTAKE; CHILDHOOD OBESITY; CLINICAL FEATURE; CRANIOPHARYNGIOMA; DAYTIME SOMNOLENCE; ENERGY BALANCE; ENERGY CONSERVATION; ENERGY EXPENDITURE; GASTRIC BANDING; GENETIC DISORDER; HORMONE DEFICIENCY; HUMAN; HYPERPHAGIA; HYPOTHALAMIC OBESITY; HYPOTHALAMUS TUMOR; INFLAMMATION; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NEUROENDOCRINE DISEASE; NEUROSURGERY; OBESITY HYPOVENTILATION HYPOTHALAMIC AUTONOMIC DYSREGULATION SYNDROME; OBESITY HYPOVENTILATION SYNDROME; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POLYSOMNOGRAPHY; PRADER WILLI SYNDROME; RADIATION INJURY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROUX Y ANASTOMOSIS; SLEEP DISORDERED BREATHING; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT GAIN; CHILD; ENERGY METABOLISM; HYPOTHALAMUS; METABOLISM; OBESITY;

CHILD; ENERGY METABOLISM; HUMANS; HYPOTHALAMUS; OBESITY;

EID: 84928956958     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2014-0512     Document Type: Review

References (119)

1. Anand BK, Brobeck JR. Localization of a "feeding center" in the hypothalamus of the rat. Proc Soc Exp Biol Med 1951;77:323-4.
2. Brobeck JR. Mechanism of the development of obesity in animals with hypothalamic lesions. Physiol Rev 1946;26:541-59.
3. King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 2006;87:221-44.
4. Williams KW, Elmquist JK. Lighting up the hypothalamus: coordinated control of feeding behavior. Nat Neurosci 2011;14:277-8.
5. Myers Jr MG, Olson DP. Central nervous system control of metabolism. Nature 2012;491:357-63.
6. Bereket A, Kiess W, Lustig RH, Muller HL, Goldstone AP, et al. Hypothalamic obesity in children. Obes Rev 2012;13:780-98.
7. Hochberg I, Hochberg Z. Expanding the definition of hypothalamic obesity. Obes Rev 2010;11:709-21.
8. Woods SC, Seeley RJ, Porte Jr D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science 1998;280:1378-83.
9. Wardlaw SL. Hypothalamic proopiomelanocortin processinGand the regulation of energy balance. Eur J Pharmacol 2011;6660:213-19.
10. Pritchard LE, White A. Neuropeptide processinGand its impact on melanocortin pathways. Endocrinology 2007;148:4201-07.
11. Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003;37:649-61.
12. Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res 2004;59:267-85.
13. Peruzzo B, Pastor FE, Blazquez JL, Schobitz K, Pelaez B, et al. A second look at the barriers of the medial basal hypothalamus. Exp Brain Res 2000;132:10-26.
14. Ibrahim N, Bosch MA, Smart JL, Qiu J, Rubinstein M, et al. Hypothalamic proopiomelanocortin neurons are glucose responsive and express KATP channels. Endocrinology 2003;144:1331-40.
15. Obici S, Feng Z, Morgan K, Stein D, Karkanias G, et al. Central administration of oleic acid inhibits glucose production and food intake. Diabetes 2002;51:271-5.
16. Cota D, Proulx K, Woods SC, Seeley RJ. The role of leucine in regulating food intake. Science 2006;313:1236-8.
17. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, et al. Brainderived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003;6:736-42.
18. Maekawa F, Fujiwara K, Toriya M, Maejima Y, Nishio T, et al. Brain-derived neurotrophic factor in VMH as the causal factor for and therapeutic tool to treat visceral adiposity and hyperleptinemia in type 2 diabetic Goto-Kakizaki rats. Front Synaptic Neurosci 2013;5:7.
19. Swanson LW, Sanchez-Watts G, Watts AG. Comparison of melanin-concentrating hormone and hypocretin/orexin mRNA expression patterns in a new parceling scheme of the lateral hypothalamic zone. Neurosci Lett 2005;387:80-4.
20. Lustig RH. Hypothalamic obesity: causes, consequences, treatment. Pediatr Endocrinol Rev 2008;6:220-7.
21. Vollenweider L, Tappy L, Owlya R, Jequier E, Nicod P, et al. Insulin induced sympathetic activation and vasodilatation in skeletal muscle. Effects of insulin resistance in lean subjects. Diabetes 1995;44:641-5.
22. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, et al. Role of leptin in fat regulation. Nature 2000;404:652-60.
23. Lustig RH. Autonomic dysfunction of the-cell and the pathogenesis of obesity. Rev Endocr Metab Dis 2003;4:23-32.
24. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
25. Guran T, Turan S, Bereket A, Akcay T, Unluguzel G, et al. The role of leptin, soluble leptin receptor, resistin, and insulin secretory dynamics in the pathogenesis of hypothalamic obesity in children. Eur J Pediatr 2009;168:1043-8.
26. Farooqi S. Obesity genes-its all about parents. Cell Metab 2009;9:487-8.
27. Maffei M, Fei H, Lee GH, Dani C, Leroy P, et al. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci USA 1995;92:6957-60.
28. Hustvedt BE, Lovo A. Correlation between hyperinsulinemia and hyperphagia in rats with ventromedial hypothalamic lesions. Acta Physiol Scand 1972;84:29-33.
29. Rohner F, Dufour AC, Karakash C, Le Marchand Y, Ruf KB, et al. Immediate effect of lesion of the ventromedial hypothalamic area upon glucose induced insulin secretion in anaesthetized rats. Diabetologia 1977;13:239-42.
30. Slaunwhite WR 3rd, Goldman JK, Bernardis LL. Sequential changes in glucose metabolism by adipose tissue and liver of rats after destruction of the ventromedial hypothalamic nuclei: effect of three dietary regimens. Metabolism 1972;21:619-31.
31. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, et al. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 2000;141:3072-9.
32. Bray GA, Inoue S, Nishizawa Y. Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 1981;20:366-77.
33. Shaikh MG, Grundy R, Kirk J. Hyperleptinaemia rather than fasting hyperinsulinaemia is associated with obesity following hypothalamic damage in children. Eur J Endocrinol 2008;159:791-7.
34. Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 1999;135:162-8.
35. Simoneau-Roy J, O'Gorman C, Pencharz P, Adeli K, Daneman D, et al. Insulin sensitivity and secretion in children and adolescents with hypothalamic obesity following treatment for craniopharyngioma. Clin Endocrinol (Oxf) 2010;72:364-70.
36. Bucher H, Zapf J, Torresani T, Prader A, Froesch ER, et al. Insulin-like growth factors I and II, prolactin, and insulin in 19 growth hormone deficient children with excessive, normal, or decreased longitudinal growth after operation for craniopharyngioma. N Engl J Med 1983;309:1142-6.
37. Sakaguchi T, Arase K, Bray GA. Sympathetic activity and food intake of rats with ventromedial hypothalamic lesions. Int J Obes 1988;12:285-91.
38. Penicaud L, Cousin B, Leloup C, Lorsignol A, Casteilla L. The autonomic nervous system, adipose tissue plasticity, and energy balance. Nutrition 2000;16:903-8.
39. Roth CL, Hunneman DH, Gebhardt U, Stoffel-Wagner B, Reinehr T, et al. Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr Res 2007;61:496-501.
40. Dun SL, Brailoiu GC, Yang J, Chang JK, Dun NJ. Cocaine and amphetamine-regulated transcript peptide and sympatho-adrenal axis. Peptides 2006;27:1949-55.
41. Wang C, Billington CJ, Levine AS, Kotz CM. Effect of CART in the hypothalamic paraventricular nucleus on feedinGand uncoupling protein gene expression. Neuroreport 2000;11:3251-5.
42. Müller HL, Handwerker G, Wollny B, Faldum A, Sorensen N. Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J Clin Endocrinol Metab 2002;87:3993-6.
43. Wolden-Hanson T, Mitton DR, McCants RI, Yellon SM, Wilkinson CW, et al. Daily melatonin administration to middle aged male rats suppresses body weight, intra abdominal adiposity, and plasma leptin, and insulin independent of food intake and total body fat. Endocrinology 2000;141:487-97.
44. Kassayova M, Markova M, Bojkova B, Adamekova E, Kubartka P, et al. Influence of long-term melatonin administration on basic physiological and metabolic variables of young Wistar Han rats. Biologia 2006;61:313-20.
45. Srinivasan V, YoOhta Y, Espino J, Pariente JA, Rodríguez AB, et al. Metabolic Syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov 2013;7:11-25.
46. Lee M, Korner J. Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans. Pituitary 2009;12:87-95.
47. Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z. 11 Beta-hydroxysteroid dehydrogenase activity in hypothalamic obesity. J Clin Endocrinol Metab 2003;88:379-84.
48. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, et al. Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 2003;88:385-93.
49. Müller HL. Craniopharyngioma. Endocr Rev 2014;35:513-43.
50. Ahmet A, Blaser S, Stephens D, Guger S, Rutkas JT, et al. Weight gain in craniopharyngioma-a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006;19:121-7.
51. Lek N, Prentice P, Williams RM, Ong KK, Burke GA, et al. Risk factors for obesity in childhood survivors of suprasellar brain tumours: a retrospective study. Acta Paediatr 2010;99:1522-6.
52. Müller HL, Bueb K, Bartels U, Roth C, Harz K, et al. Obesity after childhood craniopharyngioma-German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr 2001;213:244-9.
53. Müller HL, Emser A, Faldum A, Bruhnken G, Etavard-Gorris N, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab 2004;89:3298-305.
54. Lustig RH, Post SM, Srivannaboon K, Rose SR, Danish RK, et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003;88:611-16.
55. Gautier A, Godbout A, Grosheny C, Tejedor I, Coudert M, et al. Markers of recurrence and long-term morbidity in craniopharygioma: a systematic analysis of 171 patients. J Clin Endocrinol Metab 2012;97:1258-67.
56. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, et al. Congenital leptin deficiency is associated with severe earlyonset obesity in humans. Nature 1997;387:903-8.
57. Clément K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398-401.
58. Martinelli CE, Keogh JM, Greenfield JR, Henning E, van der Klaauw AA, et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab 2011;96:181-8.
59. Krude H, Biebermann H, Luck W, Horn R, Brabant G, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-7.
60. del Giudice EM, Santoro N, Cirillo G, D'Urso L, Di Toro R, et al. Mutational screening of the CART gene in obese children: identifying a mutation (Leu34Phe) associated with reduced resting energy expenditure and cosegregating with obesity pheno-type in a large family. Diabetes 2001;50:2157-60.
61. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997;16:303-6.
62. Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004;7:1187-9.
63. Rodríguez-López R, Pérez JM, Balsera AM, Rodríguez GG, Moreno TH, et al. The modifier effect of the BDNF gene in the phenotype of the WAGRO syndrome. Gene 2013;516:285-90.
64. Holder JL Jr, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet 2000;9:101-8.
65. Doche ME, Bochukova EG, Su HW, Pearce LR, Keogh JM, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest 2012;122:4732-6.
66. Pearce LR, Atanassova N, Banton MC, Bottomley B, van der Klaauw AA, et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell 2013;155:765-77.
67. Borman AD, Pearce LR, Mackay DS, Nagel-Wolfrum K, Davidson AE, et al. A homozygous mutation in the TUB gene associated with retinal dystrophy and obesity. Hum Mutat 2014;35:289-93.
68. Prada PO, Quaresma PG, Caricilli AM, Santos AC, Guadagnini D, et al. Tub has a key role in insulin and leptin signalinGand action in vivo in hypothalamic nuclei. Diabetes 2013;62:137-48.
69. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97.
70. Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, et al. Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet 2009;18:1323-31.
71. Patwari PP, Wolfe LF. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: review and update. Curr Opin Pediatr 2014;26:487-92.
72. Farooqi IS. Monogenic human obesity. Front Horm Res 2008;36:1-11.
73. Hinney A, Volckmar AL, Antel J. Genes and the hypothalamic control of metabolism in humans. Best Pract Res Clin Endocrinol Metab 2014;28:635-47.
74. Goldstone AP. Prader-Willi syndrome: advances in its genetics, pathophysiology and treatment. Trends Endocrinol Metab 2004;15:12-20.
75. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995;80:573-9.
76. Kweh FA, Miller JL, Sulsona CR, Wasserfall C, Atkinson M, et al. Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A 2015:167A:69-79.
77. Goldstone AP, Patterson M, Kalingag N, Ghatei MA, Brynes AE, et al. FastinGand post-prandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY 3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 2005;90:2681-90.
78. Kanumakala S, Greaves R, Pedreira C, Donath S, Warne G, et al. Fasting ghrelin levels are not elevated in children with hypothalamic obesity. J Clin Endocrinol Metab 2005;90: 2691-5.
79. Dhondt K, Verloo P, Verhelst H, Van Coster R, Overeem S. Hypocretin-1 deficiency in a girl with ROHHAD syndrome. Pediatrics 2013;132:e788-92.
80. Okonska M, Birkholz D, Korpal-Szczyrska M, Adamkiewicz-Drozynska E, Alska A, et al. The evaluation of the influence of growth hormone therapy on growing process and metabolic functions in patients after treatment of craniopharyngioma. Pediatr Endocrinol Diabetes Metab 2010;16:19-24.
81. Geffner M, Lundberg M, Koltowska-Häggström M, Abs R, Verhelst J, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab 2004;89:5435-40.
82. Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, et al. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 2004;89:81-6.
83. Hoffmann A, Postma FP, Sterkenburg AS, Gebhardt U, Müller HL. Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma. J Pediatr Endocrinol Metab 2015;28:35-43.
84. Holmer H, Pozarek G, Wirfält E, Popovic V, Ekman B, et al. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab 2010;95:5395-402.
85. Shaikh MG, Grundy RG, Kirk JMV. Reductions in basal metabolic rate and physical activity contribute to hypothalamic obesity. J Clin Endocrinol Metab 2008;93:2588-93.
86. Müller HL, Handwerker G, Gebhardt U, Faldum A, Emser A, et al. Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes Control 2006;17:583-9.
87. O'Gorman CS, Simoneau-Roy J, Pencharz P, MacFarlane J, MacLusky I, et al. Sleep-disordered breathing is increased in obese adolescents with craniopharyngioma compared with obese controls. J Clin Endocrinol Metab 2010;95:2211-18.
88. Rosen G, Brand SR. Sleep in children with cancer: case review of 70 children evaluated in a comprehensive pediatric sleep center. Support Care Cancer 2011;19:985-94.
89. Manni R, Politini L, Nobili L, Ferrillo F, Livieri C, et al. Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors. Clin Neurophysiol 2001;112:800-5.
90. Müller HL, Müller-Stover S, Gebhardt U, Kolb R, Sörensen N, et al. Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese childhood craniopharyngioma patients. J Pediatr Endocrinol Metab 2006;19:423-9.
91. Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med 2002;156:887-92.
92. Rakhshani N, Jeffery AS, Schulte F, Barrera M, Atenafu EG, et al. Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity. Obesity 2010;18:1768-74.
93. Ismail D, O'Connell MA, Zacharin MR. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab 2006;19: 129-34.
94. Greenway FL, Bray GA. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract 2008;14:697-703.
95. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003;88:2586-92.
96. Weiss R. URL: http://clinicaltrials.gov/ct2/show/NCT00076362.
97. Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, et al. Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy. Int J Pediatr Endocrinol 2011;2011:417949.
98. Cettour-Rose P, Burger AG, Meier CA, Visser TJ, Rohner-Jeanrenaud F. Central stimulatory effect of leptin on T3 produc-tion is mediated by brown adipose tissue type II deiodinase. Am J Physiol Endocrinol Metab 2002;283:E980-7.
99. Fernandes JK, Klein MJ, Ater JL, Kuttesch JF, Vassilopoulou-Sellin R. Triiodothyronine supplementation for hypothalamic obesity. Metabolism 2002;51:1381-3.
100. Danielsson P, Janson A, Norgren S, Marcus C. Impact of sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J Clin Endocrinol Metab 2007;92:4101-6.
101. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010;123:468.e9-17.
102. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16.
103. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br Med J 2012;344:d7771.
104. Shirazi R, Palsdottir V, Collander J, Anesten F, Vogel H, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci USA 2013;110:16199-204.
105. Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 2013;168:699-706.
106. Simmons JH, Shoemaker AH, Roth CL. Treatment with glucagon-like peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor. Horm Res Paediatr 2012;78:54-8.
107. Thondam SK, Cuthbertson DJ, Aditya BS, Macfarlane IA, Wilding JP, et al. A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2012;77:635-7.
108. Ando T, Haraguchi A, Matsunaga T, Natsuda S, Yamasaki H, et al. Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity. Intern Med 2014;53:1791-5.
109. She M, Deng X, Guo Z, Laudon M, Hu Z, et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res 2009;59:248-53.
110. Oxenkrug GF, Summergrad P. Ramelteon attenuates ageassociated hypertension and weight gain in spontaneously hypertensive rats. Ann NY Acad Sci 2010;1199:114-20.
111. Müller HL, Gebhardt U, Wessel V, Schröder S, Kolb R, et al. First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity. Klin Padiatr 2007;219:323-5.
112. Schultes B, Ernst B, Schmid F, Thurnheer M. Distal gastric bypass surgery for the treatment of hypothalamic obesity after childhood craniopharyngioma. Eur J Endocrinol 2009;161:201-6.
113. Inge TH, Pfluger P, Zeller M, Rose SR, Burget L, et al. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract 2007;3:606-9.
114. Bretault M, Boillot A, Muzard L, Poitou C, Oppert JM, et al. Clinical review: bariatric surgery following treatment for craniopharyngioma: a systematic review and individuallevel data meta-analysis. J Clin Endocrinol Metab 2013;98:2239-46.
115. Elowe-Gruau E, Beltrand J, Brauner R, Pinto G, Samara-Boustani D, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013;98:2376-82.
116. Clark AJ, Cage TA, Aranda D, Parsa AT, Sun PP, et al. A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst 2013;29:231-8.
117. Spoudeas HA, Saran F, Pizer B. A multimodality approach to the treatment of craniopharyngiomas avoiding hypothalamic morbidity: a UK perspective. J Pediatr Endocrinol Metab 2006;19:447-51.
118. Puget S, Garnett M, Wray A, Grill J, Habrand JL, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007;106:3-12.
119. Mallucci C, Pizer B, Blair J, Didi M, Doss A, et al. Management of craniopharyngioma: the Liverpool experience following the introduction of the CCLG guidelines. Introducing a new risk assessment grading system. Childs Nerv Syst 2012;28:1181-92.